+1-888-308-5802      . .

Rune Labs & BlueRock collaborate for research on Parkinson’s disease

Author : Pankaj Singh | Published Date : 2023-03-17 

Rune Labs & BlueRock collaborate for research on Parkinson’s disease

Rune Labs, a neurology software and data platform provider, has recently announced a collaboration with biopharmaceutical firm BlueRock Therapeutics, a wholly owned subsidiary of Bayer AG. BlueRock will use the clinical trial technology of Rune Labs featuring patient monitoring and data collection facilities, named StriveStudy, to delve into the root cause of the Parkinson’s disease.

This is the first partnership of both companies with each other and is also the first deployment of the StriveStudy clinical trial platform, in order to facilitate better research of therapeutics to treat movement disorders. Rune Labs’ technology will be used by BlueRock in a non-interventional study to capture Parkinson’s symptoms data through Apple Watch-enabled tools for data collection and remote patient monitoring.

The CEO of Rune Labs, Brian Pepin, has shared that the research on Parkinson’s disease has been limited in the past, since people who suffer from the disorder display varying sets of symptoms. Furthermore, subjective tools commonly used by researchers, such as patient-reported questionnaires, are unable to capture the dynamic nature of the disease, he added. Through this collaboration, claims Pepin, the companies will work on establishing a baseline dataset for symptoms of Parkinson’s disease to fully derive benefits from advanced therapies and increase the efficiency of future clinical trials.

According to President and CEO of BlueRock Therapeutics, Seth Ettenberg, the firm is looking forward to partnering with Rune Labs to drive progress in the development of medical therapy for diseases such as Parkinson’s.

Rune Labs is also providing a first-hand chance to conduct trials for and streamline BlueRock’s stem cell-based therapy bemdaneprocel technology. Through StriveStudy, BlueRock will be able to conduct subsequent data analysis on baseline and follow-up data, including dyskinesias, to gain a more comprehensive understanding of the therapeutic advantages of the first-in-class therapy.

For the record, RuneLabs is a data analytics company that is involved in precision neurology therapy development.  The firm has financial help from various investors like Eclipse Ventures, DigiTx, and Moment Ventures, among others.

Source Credit: https://www.prnewswire.com/news-releases/bluerock-therapeutics-to-use-rune-labs-clinical-trial-platform-to-better-characterize-parkinsons-disease-state-in-cell-therapy-trials-301771114.html

About Author

Pankaj Singh . .

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Swiss National Bank extends helping hand for revival of Credit Suisse

Swiss National Bank extends helping hand for revival of Credit Suisse

Published Date: 2023-03-17         Author: Pankaj Singh

Credit Suisse has reportedly decided to borrow USD 53.68 billion from the Swiss National Bank, under a short-term liquidity and covered loan facility. The decision has been made in an attempt to try to rejuvenate operations following a fall in shares after Saudi National Bank, its top investor, with... Read More>>

Netherlands declares strict policies regarding microchip export to China

Netherlands declares strict policies regarding microchip export to China

Published Date: 2023-03-10         Author: Pankaj Singh

The Netherlands has reportedly decided to put into effect certain restrictions on the export of microchip equipment to China for the reason of national security. The Dutch government is following a similar move made by the U.S. This move will limit the export of products from chip equipment manufact... Read More>>

Availability of funds for venture deals in Singapore dips in 2022

Availability of funds for venture deals in Singapore dips in 2022

Published Date: 2023-03-03         Author: Pankaj Singh

The capital funding required to set up ventures by tech companies in Singapore reportedly weakened in 2022 on account of a disturbance in the macroeconomic environment that made investors cautious. The volume of deals dropped by 11 percent to 651 Y-o-Y, while the total deal volume went down to USD 1... Read More>>

© 2023 Fractovia. All Rights Reserved